RSS-Feed abonnieren
DOI: 10.1055/s-0038-1653408
Effects of Suloctidil on Platelet Survival Time Following Cardiac Valve Replacement
Publikationsverlauf
Received 12. Januar 1981
Accepted 02. Juli 1981
Publikationsdatum:
05. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/198102/lookinside/thumbnails/10-1055-s-0038-1653408-1.jpg)
Summary
Platelet functions and blood clotting parameters were examined in 23 patients with a shortened platelet survival time after cardiac valve replacement.
Treatment was given at random: for a first group antivitamins K with suloctidil and for the second group antivitamin K alone.
Six weeks of treatment with antivitamin K alone did not induce any significant change in the platelet survival time, platelet retention or platelet factor 4 in plasma.
In contrast, the shortened platelet survival time increased significantly after 6 weeks of treatment with suloctidil. Moreover the platelet retention and the amount of platelet factor 4 in plasma were significantly reduced, indicating that normalization of platelet survival is the result of decreased destruction, presumably at the level of the prosthetic surface. The clinical benefits expected from these results remain to be validated by a longer follow up period.
-
References
- 1 Starr A, Grunkemeier G, Lambert L, Okies JE, Thomas D. Mitral valve replacement. A 10 year follow-up of non cloth-covered vs cloth-covered caged-ball prostheses Circulation 1976; 54 suppl (Suppl. 03) 47-56
- 2 Roberts WC, Hammer WJ. Cardiac pathology after valve replacement with a tilting disc prostesis (Björk-Shiley Type). A study of 46 necropsy patients and 49 Björk-Shiley prostheses Am J Cardiol 1976; 37: 1024-1033
- 3 Cohn LH, Mudge GH, Pratter F, Collins JJ. Five to eight year follow-up of patients undergoing porcine heart-valve replacement. N Engl J Med 1981; 304: 258-262
- 4 Bamhorst DA, Oxman HA, Connolly DC. Isolated replacement of the mitral valve with the Starr-Edwards prosthesis. J Thorac Cardiovasc Surg 1976; 71: 230-237
- 5 Bamhorst DA, Oxman HA, Connolly DC. Long term follow-up of isolated replacement of the aortic and mitral valve with the StarrEdwards prosthesis. Am J Cardiol 1975; 35: 228-233
- 6 Taguchi K, Matsumara H, Washizu T, Hirao M, Kato K, Kato E, Mochizvki T, Takamura K, Mashimo I, Morifuji K, Nakagak M, Juma T. Effect of athrombogenic therapy, especially high dose therapy of Dipyridamole after prosthetic valve replacement. J Cardiovasc Surg 1975; 16: 8-15
- 7 Steele P, Weily H, Davies H, Pappas G, Genton E. Platelet survival time following aortic valve replacement. Circulation 1975; 51: 358-362
- 8 Sutton MG, Miller GA H, Oldershaw PJ, Paneth M. Anticoagulants and the Björk-Shiley prosthesis. Experience of 390 patients Br Heart J 1978; 40: 558-562
- 9 Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med 1970; 283: 1302-1305
- 10 Weily H, Steele P, Davies H. Platelet survival in patients with substitute heart valves. N Engl J Med 1974; 290: 534-537
- 11 Sullivan JM, Harken DE, Gorlen R. Pharmacologic control of thromboembolic complications of cardiac valve replacement. N Engl J Med 1971; 284: 1391-1394
- 12 Dale Myhre E, Rootwelt K. Effects of dipyridamole and acetylsalicylic acid on platelet functions in patients with aortic ballvalve prostheses. Am Heart J 1975; 89: 613-618
- 13 Weily H, Genton E. Altered platelet function in patients with prosthetic mitral valves. Effects of sulfinpyrazone therapy Circulation 1970; 42: 967-972
- 14 Steele P, Rainwater J, Vogel R. Platelet suppressant therapy in patients with prosthetic cardiac valves. Relationship of clinical effectiveness to alteration of platelet survival time Circulation 1979; 60: 910-913
- 15 Roba J, Bourgain R, Andries R, Claeys M, Van Opstal M, Lambelin G. Antagonism by suloctidil of arterial thrombus formation in rats. Thromb Res 1976; 9: 585-594
- 16 De Gaetano G, Miragliotta G, Roncucci R, Lansen J, Lambelin G. Suloctidil: a novel inhibitor of platelet aggregation in human beings. Thromb Res 1976; 8: 361-371
- 17 Gurewich V, Lipinski B. Evaluation of antithrombotic properties of suloctidil in comparison with aspirin and dipyridamole. Thromb Res 1976; 9: 101-108
- 18 Aster RH, Jandl JH. Platelet sequestration in man. I. Methods. J Clin Invest 1964; 43: 843-855
- 19 Bowie EJ W, Owen OH A, Thompson JH, Didsheim P. A test of platelet adhesiveness. Mayo Clin Proc 1969; 44: 306-308
- 20 Born GV R. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
- 21 Hurlet-Birk JensenA, Legrand-Monsieur A, Masure R. Analysis of heparin neutralizing assay conditions. Thromb Res 1978; 13: 609-614
- 22 Vermylen C, Verstraete M. A simple method for the assay of factor VIII using 25 microliters of capillary blood. Br J Haemat 1968; a 14: 241-245
- 23 Laurell CB. Antigen antibody crossed electrophoresis. Ann Biochem 1965; 10: 358-361
- 24 Buckell M. The effect of citrate on euglobulin methods of estimating fibrinolytic activity. J Clin Path 1958; 2: 405-410
- 25 Dawes J, Smith RC, Pepper DS. The release, distribution and clearance of human betathromboglobulin and platelet factor 4. Thromb Res 1978; 12: 851-861
- 26 Okuno T, Crockatt D. Platelet factor 4 activity and thrombo-embolic episodes. Am J Clin Pathol 1977; 67: 351-355
- 27 Verhaeghe R, Vanhoof A. The concomitant use of suloctidil and a long acting oral anticoagulant. Acta Clin Bel 1977; 32: 36-38